ArticleJournal of viral hepatitis2008
Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters.
Article in Journal of viral hepatitis, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00545558 (Antiretroviral Therapy and the Hepatitis C Virus), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Antiretroviral Therapy and the Hepatitis C Virus
Who cites it
10 citing papers in PubMed.
- In-host modeling.Infectious Disease Modelling · 2017Article
- A hepatitis C virus infection model with time-varying drug effectiveness: solution and analysis.PLoS computational biology · 2014Article
- Using time-delayed mutual information to discover and interpret temporal correlation structure in complex populations.Chaos (Woodbury, N.Y.) · 2012Article
- Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin.Medical science monitor : international medical journal of experimental and clinical research · 2011Article
- IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection.The Journal of infectious diseases · 2011Article
- A perspective on modelling hepatitis C virus infection.Journal of viral hepatitis · 2010Review
- Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling.Critical reviews in immunology · 2010Review
- Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment.The Journal of infectious diseases · 2009Article
- Modeling HCV kinetics under therapy using PK and PD information.Expert opinion on drug metabolism & toxicology · 2009Review
- Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon alpha-2b.Journal of viral hepatitis · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Neumann et al. [1] developed a widely used model for the analysis of hepatitis C virus (HCV) dynamics after the initiation of interferon therapy that assumes the effectiveness of therapy in blocking virion production, epsilon, is constant. However, with pegylated interferon alpha-2b (PEG-IFN) given weekly, there are significant changes in drug concentration between doses, leading to changes in drug effectiveness and viral rebounds. To investigate the appropriateness of the constant effectiveness (CE) model [1] for studies involving PEG-IFN, we simulated PEG-IFN treatment, using 294 sets of pharmacokinetic/pharmacodynamic (PK/PD) parameters that span observed ranges and fit the simulated data to the CE model. For most combinations of PK/PD parameters, the fits resulted in an infected cell loss rate, delta, that underestimates the true value used in the simulations and yielded over-estimates of the average effectiveness of PEG-IFN. In the setting of PEG-IFN therapy, the use of the CE model of HCV kinetics has to be reevaluated and the validity of its use depends on the amount of HCV RNA rebound observed between doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.